Equifax reported earnings on July 21 and the Street's response was swift and unified — a wave of target cuts from across the analyst community, landing on a stock that had already given back most of its post-Q2 gains.
The analyst reaction tells the clearest story this week. Four firms lowered price targets on July 22 alone, all while maintaining their existing ratings. Baird kept its Outperform but trimmed to $232 from $245. RBC Capital also held Outperform and cut harder, dropping to $194 from $222. Needham stayed at Buy with a new $245 target, down from $265. Barclays, the lone Equal-Weight in the group, moved to $200 from $215. The consensus mean now sits at $210.52 — still 22% above Tuesday's close of $173 — but the direction of travel is clearly lower. No firm upgraded. No firm held a target steady. The message from the Street is that estimates came in too high, and the bar needs resetting even if the longer-term conviction remains intact.
The day's price action reinforced the reset. The stock fell 3.9% on July 21 following the print, reversing most of the week's earlier gains. That follows the 7.6% one-day pop from the Q2 event on July 15, which the previous note flagged as the catalyst for fresh short rebuilding. That rebuilding has continued. Short interest climbed to 5.2% of free float on July 21 — essentially unchanged on the week but up 9% over the past month, and still near the top of the 30-day range. Bears added through the post-Q2 rally and have not covered after the subsequent decline. The borrow market remains extremely loose, with availability running near 2,687% of short interest and cost to borrow at just 0.42%. New short positions are being established cheaply. This is not a squeeze setup — it is a conviction trade against a stock the market believes rallied too far.
Options, meanwhile, have turned markedly less defensive than they were heading into the print. The put/call ratio eased to 0.80, almost exactly in line with its 20-day mean and a z-score near zero. That is a sharp reversal from the reading above 0.88 flagged in the prior earnings preview, when options traders were loading up on downside protection. The hedges have been monetised or rolled off. The options market now looks neutral rather than braced.
On valuation, the PE multiple sits at 18.2x trailing earnings — up roughly 1.9 turns over the past month despite the stock's flat-to-down performance, which implies that earnings estimates have been cut faster than the share price has fallen. The EV/EBITDA of 11.2x has compressed 0.6 turns over the same period, suggesting the market is paying less for operating earnings. Factor scores offer some support: EPS momentum ranks in the 68th percentile on a 30-day basis, and the dividend score ranks in the 99th percentile. Against peers, TransUnion fell 3.8% on the day and Paychex dropped 2.8%, suggesting broad sector pressure rather than Equifax-specific selling — though the magnitude of EFX's decline was larger than most.
The bull case rests on mid-single-digit USIS growth, EBITDA margin expansion, and the FICO pricing tailwind in mortgage. The bear case centres on mortgage origination volume risk, international slowdown, and the long shadow of execution risk. With the print now digested, borrow still cheap, and analysts still trimming targets, the next few sessions will clarify whether shorts are satisfied with their position or continue adding into weakness.
See the live data behind this article on ORTEX.
Open EFX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
